Unguentine Original Pain Relief Ointment Recalled for Manufacturing Process Deviations
Unguentine Original Pain Relief Ointment is being recalled due to manufacturing process deviations. The FDA-led voluntary recall affects nationwide distribution.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II voluntary precautionary recall with no reported illnesses or injuries. The recall is due to manufacturing process deviations without a specific identified health hazard.
Plain-English summary
Ecometics, Inc. has initiated a voluntary recall of Unguentine Original Maximum Strength Pain Relieving/Antiseptic Ointment due to manufacturing process deviations. The product is packaged in 1 oz. (28.3g) metal tubes containing Camphor 3.0%, Phenol 2.5%, Tannic Acid 2.2%, and other active ingredients.
The recall affects two lot numbers: 1E346A with expiration November 2023 and 2E304A with expiration October 2024. The product was distributed nationwide throughout the United States by Oakhurst Company, Levittown, New York.
Consumers who have purchased this product should stop using it immediately. Contact Ecometics, Inc. or Oakhurst Company for instructions on how to return the product or obtain additional information.
The recalled product
- Product
- Unguentine Original Maximum Strength Pain Relieving/Antiseptic Ointment (Camphor 3.0%, Phenol 2.5%, Tannic Acid 2.2%, Oxide 6.6%), packaged in 1 oz. (28.3g) metal tubes, Distributed by: Oakhurst Company Levittown, NY 11756
- Manufacturer
- Ecometics, Inc.
- Category
- Drug — Topical Ointment
- Hazard
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 1E346A
- Exp. Date Nov-23
- 2E304A
- Exp. Date Oct-24
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27